William C Patton, MD in Forrest City, AR - Pediatrics

William C Patton, MD is a Pediatrics physician based in Forrest City, Arkansas. William C Patton is licensed to practice in Arkansas (license number N-6317) and his current practice location is 901 Holiday Dr, Forrest City, Arkansas. He can be reached at his office (for appointments etc.) via phone at (870) 633-0880.

NPI number for William C Patton is 1871528240 and his current mailing address is 901 Holiday Dr, Forrest City, Arkansas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1871528240.

Contact Information

	William C Patton, MD
	901 Holiday Dr, Forrest City, AR 72335-9183
	(870) 633-0880
	(870) 633-3801

Physician's Profile

Full Name	William C Patton
Gender	Male
Speciality	Pediatrics
Location	901 Holiday Dr, Forrest City, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1871528240
Provider Enumeration Date: 07/12/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for William C Patton such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1871528240	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208000000X	Pediatrics	N-6317 (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. William C Patton is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
William C Patton, MD 901 Holiday Dr, Forrest City, AR 72335-9183 Ph: (870) 633-0880	William C Patton, MD 901 Holiday Dr, Forrest City, AR 72335-9183 Ph: (870) 633-0880

News Archive

Electroconvulsive therapy and how it works in severe depression: Study

Electroconvulsive therapy, or ECT, has been used in severely and persistently depressed patients from their disabling mood state for more than seven decades. Researchers have searched for the reason why this technique sometimes works in these patients.

Forest, Merz settle NAMENDA patent infringement litigation

Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest's NAMENDA® (memantine hydrochloride) immediate release tablets.

UT Southwestern Medical Center receives NIH funds for asthma research

UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that data from a phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were published in The Lancet. This study met its primary endpoint, resulting in an average LDL-C reduction of greater than 100 mg/dL in this very high-risk patient population.

Biothera's Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

William C Patton, MD - Pediatrics in Forrest City, AR